Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 21 art units • 22 examiners • 0 of 23 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Biogen Ma Inc. has 22 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 21 distinct examiners and 20 distinct art units. LALONDE, ALEXANDRA ELIZABETH, is the busiest examiner with 2 pending office actions.
The near-matching examiner and art-unit counts show broad distribution across the biotechnology and pharmaceutical examination landscape. Portfolio management therefore calls for matter-level tracking rather than reliance on a single examiner relationship. The identified busiest examiner has a limited share of the pending activity, so counsel should maintain separate strategies for the other examiner and art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (4%) |
| §103 only | 4 (17%) |
| §102 only | 1 (4%) |
| §112 only | 3 (13%) |
| Double-patenting + other | 5 (22%) |
| Multi-statute (no §101) | 9 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LALONDE, ALEXANDRA ELIZABETH | 2 | 71.2% | +32.8% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| MEDWAY, SCOTT J | 1 | 66.6% | +23.0% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17380694 | MONITORING BASED ON CONTINUOUS INTRACRANIAL EEG ACTIVITY | SHOSTAK, ANDREY | 118d overdue |
| 19172111 | METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY | SHIN, DANA H | — |
| 18765894 | MEDICAL DEVICE HAVING NON-FILTERED CSF WITHDRAWAL PATHWAY | MEDWAY, SCOTT J | — |
| 18571090 | SYNTHETIC PREPARATION FOR DIROXIMEL FUMARATE | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18567674 | METHODS FOR TREATING ALZHEIMER'S DISEASE | CHERNYSHEV, OLGA N | — |
| 18286721 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC ACTIVE WHITE MATTER LESIONS / RADIOLOGICALLY ISOLATED SYNDROME | AEDER, SEAN E | — |
| 18283925 | NUCLEIC ACID DELIVERY TO THE CENTRAL NERVOUS SYSTEM | LEITH, NANCY J | — |
| 18273053 | MICROTUBULE DESTABILIZER ADDITIVES TO INCREASE RECOMBINANT VIRAL VECTOR TITERS | GRIZER, CASSANDRA SENN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18742011 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR PURIFICATION OF OLIGONUCLEOTIDES | GALSTER, SAMUEL LEONARD | 12d |
| 19172111 | METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY | SHIN, DANA H | — |
| 19048181 | METHODS OF TREATING MULTIPLE SCLEROSIS | BAEK, BONG-SOOK | — |
| 19037765 | ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF | CHEONG, CHEOM-GIL | — |
| 18864351 | CRYSTALLINE POLYMORPHS OF N-METHYL-N-((1S,3S)-3-METHYL-3-((6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL)OXY)CYCLOBUTYL)ACRYLAMIDE | NEAGU, IRINA | — |
| 18837245 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18765894 | MEDICAL DEVICE HAVING NON-FILTERED CSF WITHDRAWAL PATHWAY | MEDWAY, SCOTT J | — |
| 18717244 | METHODS AND SYSTEMS FOR TRANSFECTING HOST CELLS | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 3783 | 3 |
| 1635 | 1 |
| 1615 | 1 |
| 1645 | 1 |
| 1629 | 1 |
| 1627 | 1 |
| 1693 | 1 |
| 1653 | 1 |
| 1625 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19172111 | METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY | SHIN, DANA H | 1635 | §103DP | Non-Final OA | — | Pending | Apr 07, 2025 |
| 19048181 | METHODS OF TREATING MULTIPLE SCLEROSIS | BAEK, BONG-SOOK | 1615 | §103§112DP | Non-Final OA | — | Pending | Feb 07, 2025 |
| 19037765 | ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF | CHEONG, CHEOM-GIL | 1645 | §112DP | Non-Final OA | — | Pending | Jan 27, 2025 |
| 18864351 | CRYSTALLINE POLYMORPHS OF N-METHYL-N-((1S,3S)-3-METHYL-3-((6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL)OXY)CYCLOBUTYL)ACRYLAMIDE | NEAGU, IRINA | 1629 | §102§112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18837245 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18765894 | MEDICAL DEVICE HAVING NON-FILTERED CSF WITHDRAWAL PATHWAY | MEDWAY, SCOTT J | 3783 | §102§103Other | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18742011 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR PURIFICATION OF OLIGONUCLEOTIDES | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | 12d | Pending | Jun 13, 2024 |
| 18717244 | METHODS AND SYSTEMS FOR TRANSFECTING HOST CELLS | BARRON, SEAN C | 1653 | §103 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18709273 | BTK INHIBITORS | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18692541 | DIROXIMEL FUMARATE PARTICLES HAVING IMPROVED FLOW PROPERTIES AND METHODS OF MAKING SAME | JARRELL, NOBLE E | 1699 | §102 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18397190 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | VU, JAKE MINH | 1618 | §112Other | Non-Final OA | — | Pending | Dec 27, 2023 |
| 18571090 | SYNTHETIC PREPARATION FOR DIROXIMEL FUMARATE | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18567674 | METHODS FOR TREATING ALZHEIMER'S DISEASE | CHERNYSHEV, OLGA N | 1675 | §101§103§112 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18286721 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC ACTIVE WHITE MATTER LESIONS / RADIOLOGICALLY ISOLATED SYNDROME | AEDER, SEAN E | 1642 | §102§103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18283925 | NUCLEIC ACID DELIVERY TO THE CENTRAL NERVOUS SYSTEM | LEITH, NANCY J | 1636 | §102§103§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18283614 | REDUCING HOST CELL IMPURITIES DURING RECOMBINANT PROTEIN PRODUCTION | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | — | Pending | Sep 22, 2023 |
| 18273053 | MICROTUBULE DESTABILIZER ADDITIVES TO INCREASE RECOMBINANT VIRAL VECTOR TITERS | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18196506 | IMPLANTABLE MEDICAL DEVICE AND SYSTEM | LALONDE, ALEXANDRA ELIZABETH | 3783 | §103§112 | Non-Final OA | — | Pending | May 12, 2023 |
| 18036620 | BIPHASIC SUBCUTANEOUS DOSING REGIMENS FOR ANTI-VLA-4 ANTIBODIES | MIDDLETON, DANAYA L | 1674 | §102§103§112DP | Final Rejection | 79d overdue | Pending | May 11, 2023 |
| 18300339 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES | KIM, YUNSOO | 1641 | §103§112 | Non-Final OA | — | Pending | Apr 13, 2023 |
| 18021643 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | CORNET, JEAN P | 1628 | §103Other | Non-Final OA | 49d overdue | Pending | Feb 16, 2023 |
| 18070029 | IMPLANTABLE INTRAVENTRICULAR SAMPLING AND INFUSION ACCESS DEVICE | LALONDE, ALEXANDRA ELIZABETH | 3783 | §103§112 | Non-Final OA | — | Pending | Nov 28, 2022 |
| 17380694 | MONITORING BASED ON CONTINUOUS INTRACRANIAL EEG ACTIVITY | SHOSTAK, ANDREY | 3791 | §103§112 | Non-Final OA | 118d overdue | Pending | Jul 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiogen Ma Inc. has 23 pending office actions as of October 2026, spread across 21 art units and 22 examiners.
Alexandra Elizabeth Lalonde has the most, with 2 of Biogen Ma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
